Drug delivery companies develop technologies, formulations and platforms that control how, where and when therapeutic agents are released in the body. The field focuses on improving treatment efficacy, reducing side effects and helping medicines reach their intended targets safely and efficiently.
This category includes companies working on:
Browse 119 UK drug delivery companies below.
Convection enhanced delivery consulting and devices for CNS therapeutics
Neurochase is a contract research and consulting organisation specialising in targeted drug delivery to the CNS using convection enhanced delivery. Working with pharmaceutical and biotechnology companies, it designs and optimises delivery strategies for gene therapies and other treatments directed at specific brain…
Preclinical mRNA nanoparticle therapeutics for chronic inflammatory disease
EVolution Therapeutics is a preclinical-stage biotechnology company developing mRNA nanoparticle and hydrogel-based therapeutics to resolve chronic inflammation and support tissue repair. Spun out of Aston University, its platform delivers mRNA encoding pro-resolving proteins directly to sites of disease. The lead…
Multivalent linker technologies for antibody-drug conjugate therapeutics
Spirea is a biopharmaceutical company developing antibody-drug conjugate technologies for targeted cancer treatment. Its multivalent linker platform is designed to attach a wider range of drug payloads to antibodies while enabling higher payload loading and controlled delivery. Spirea conducts preclinical research on…
Full-service CRO and pharmacovigilance services for biopharma
Ergomed is a global contract research organisation providing clinical development, pharmacovigilance, and regulatory compliance services to the pharmaceutical and biotechnology industries. Operating across more than 100 countries, the group manages Phase I to IV clinical trials with particular depth in oncology and…
In vivo nanoparticle screening for genetic medicine delivery
Ride Therapeutics is a joint University of Cambridge and Harvard spin-out developing nanoparticle delivery systems for mRNA and gene-editing medicines. Its Molecular Logistics platform engineers and screens large libraries of non-viral carriers in living systems, measuring tissue and cell-type targeting to train an…
Biopharmaceutical group distributing and developing cannabis-based medicines
GROW Group is a biopharmaceutical company focused exclusively on cannabis-based medicines, operating through complementary distribution and research divisions. Its UK distribution arm, Grow Group UK, is a licensed GMP specials manufacturer supplying prescribed cannabinoid medicines to patients via specialist…
Crystal and particle engineering to improve drug performance
CrystecPharma is a pharmaceutical technology company that uses supercritical fluid processing to engineer drug crystals and particles. Its platform improves the dissolution, stability and delivery of small and large molecule medicines, including inhaled powders. The company provides formulation and process development…
Tissue-targeted gene and RNA delivery platforms for rare and neurological disease
Dawn Therapeutics is a pre-clinical biotechnology company developing precision delivery platforms for genetic medicines targeting the central nervous system, cartilage, and bone. Its transferrin receptor-guided system is designed to cross the blood-brain barrier and deliver RNA or DNA payloads to neuronal tissues,…
Topical peptide therapeutics targeting inflammatory skin disease
Carocell Bio is a pre-clinical stage biotechnology company developing proprietary peptide-based therapeutics for inflammatory diseases. Its pipeline centres on topical formulations that inhibit mitogen-activated protein kinase (MAPK/p38), a key regulator of the inflammatory cascade. Lead programmes target atopic…
Exosome-delivered gene editing therapies for neurodegenerative diseases
Evox Therapeutics is a biotechnology company developing exosome-based gene editing therapies for rare, genetically driven neurodegenerative diseases. Its proprietary platform uses engineered exosomes to deliver CRISPR-based gene editors across the blood-brain barrier, enabling targeted genetic intervention in the…
Global biopharma with major UK R&D and regulatory operations
Pfizer Limited is the principal UK subsidiary of Pfizer Inc., one of the world's largest biopharmaceutical companies. Its Sandwich, Kent site houses pharmaceutical sciences, global clinical supplies, quality assurance, and worldwide safety and regulatory operations serving over 175 markets. A Devices Centre of…
Cell-specific mRNA delivery platform for genetic medicines
Nuntius Therapeutics is a London-based biotechnology company developing mRNA therapies using proprietary peptide dendrimer and lipid-based nanocarriers designed to deliver genetic payloads to tissues and cell types beyond the liver. The platform combines machine learning-guided carrier design with engineered mRNA…
Inhaled therapies for COPD and chronic respiratory diseases
Verona Pharma is a biopharmaceutical company developing and commercialising inhaled therapies for chronic respiratory diseases. Its lead product, ensifentrine, is a first-in-class dual inhibitor of PDE3 and PDE4 that combines bronchodilator and non-steroidal anti-inflammatory activity in a single inhaled compound.…
Clinical-stage biopharma improving nucleoside analogue chemotherapy efficacy
NuCana is a clinical-stage biopharmaceutical company developing a pipeline of cancer medicines using proprietary phosphoramidate prodrug chemistry. Its approach transforms established nucleoside analogue chemotherapy agents into modified forms that bypass key tumour resistance mechanisms, delivering higher…
Next-generation lipid nanoparticle platform for RNA vaccines and medicines
NeoVac is a biotechnology company developing a next-generation lipid nanoparticle platform to improve the delivery of RNA vaccines and therapeutics. Its library of fully biodegradable, tissue-targeted LNPs addresses limitations of first-generation formulations, offering enhanced thermostability, multiple routes of…
Single-pill fixed-dose combinations for cardiometabolic disease
George Medicines is a late-stage biopharmaceutical company developing innovative single-pill, fixed-dose combination therapies for cardiometabolic diseases. Rather than pursuing early drug discovery, the company reformulates established best-in-class small molecules into novel proprietary low-dose combinations…
CreaTap antibody engineering for improved solid tumour penetration
Creasallis is a biotechnology company developing antibody engineering technologies intended to improve drug delivery into solid tumours. Its patented CreaTap platform modifies therapeutic antibodies to promote deeper penetration into tumour tissue. The approach is under development for monoclonal antibodies,…
Elastomer components and tooling for injectable and inhaled medicines
West Pharmaceutical Services is a global supplier of containment and delivery components for injectable medicines, including elastomer stoppers, seals and plungers for vials, syringes and cartridges. Its UK operations manufacture compression-moulded rubber seals and gaskets for metered dose inhalers and produce the…
Integrated formulation, GMP manufacture and Phase I clinical trials
BDD Pharma is a contract research and manufacturing organisation offering an integrated Lean Clinical Development pathway that combines formulation development, GMP manufacture, and Phase I clinical trials under one roof. The approach eliminates handoffs between separate service providers, reducing time to…
AAV gene therapy targeting the seizure focus in refractory epilepsy
Focalis Bio is a biotechnology company developing gene therapies for focal refractory epilepsy, a condition in which seizures arise from a specific brain region and do not respond to antiseizure medicines. Its lead programme, EPY201, is an AAV9-based gene therapy delivered locally via catheter directly to the…